The anti-angiogenic effects of targeted small molecule-based drugs, i.e., sunitinib and axitinib, are mediated by the direct blockade of VEGFR and PDGFR expressed on cancer and especially on endothelial cells [35]. The gene discussed is KDR; the disease is cancer.